pillbase.ru

MONJUVI

Active substance: tafasitamab

INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION · TAFASITAMAB 200 mg/5mL

United StatesActive

Marketing holder: Incyte Corporation

Verified 2026-10-09 · openFDA NDC

Analogues in other countries
Composition
Analogues by country

Products with the same active substance registered in other countries.

CountryProducts
RU 1
  • Минджуви®
    лиофилизат для приготовления концентрата для приготовления раствора для инфузий, 200 мг, 200 мг (original in Russian, GRLS)
    ЛП-№(015103)-(РГ-RU)
    Общество с ограниченной ответственностью "Свикс Хэлскеа" (ООО "Свикс Хэлскеа")
EU 1
  • Minjuvi
    tafasitamab
    EMEA/H/C/005436
    Incyte Biosciences Distribution B.V.
Import and control

Control by country

  • Russiaprescription only

    Source: GRLS (Russian state register) · record 01a120c3-e9e5-7c77-9c17-c82d27f8e1c3;count=1 · valid from 2026-10-09 · verified 2026-10-09

  • United Statesprescription only

    Source: openFDA NDC · record 01a12098-be81-7a3f-a89d-c200e8189972,01a1209c-1ef6-7291-be2f-aad2d96bae9b;count=2 · valid from 2026-10-09 · verified 2026-10-09

More on control status
Registration
Registration number
73535-208
Registration status
Active
Dispensing
Prescription only
Route
INTRAVENOUS
Sources
  • product · openFDA NDC · 73535-208 · Verified 2026-10-09 · open in source
  • registration_status · openFDA NDC · 73535-208 · Verified 2026-10-09 · open in source
  • ingredients.0 · openFDA NDC · 73535-208 · Verified 2026-10-09 · open in source